Acorda Therapeutics acorda.com

Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury (SCI and related neurological conditions, including multiple sclerosis (MS. The Companyƒ-s lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS. Acordaƒ-s technology platform includes two remyelinating agents in preclinical development for MS. They include M1, a class of human monoclonal antibodies, and GGF2, a product of the neuregulin 1 gene. Bo...Show all

Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury (SCI and related neurological conditions, including multiple sclerosis (MS. The Companyƒ-s lead product, Fampridine-SR, is in Phase 3 clinica...Show all

See All Exits Recent Exits

Phone: 914-347-4300

Fax:

420 Saw Mill River Road

Ardsley, 10502
New York, United States

Acorda Therapeutics - Investments & Acquisitions

Show Real Data Acorda Therapeutics Investments
See all Recent Investments
Date Company Round Amount Co-investors
2016-01-19Biotie TherapiesAcq - P2P
2014-10-22Civitas TherapeuticsAcquired
2013-04-17NeurogesxAcq - P2P
2012-12-21NeuronexAcquired
See all 4 investments